CA2767614C - Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes - Google Patents

Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes Download PDF

Info

Publication number
CA2767614C
CA2767614C CA2767614A CA2767614A CA2767614C CA 2767614 C CA2767614 C CA 2767614C CA 2767614 A CA2767614 A CA 2767614A CA 2767614 A CA2767614 A CA 2767614A CA 2767614 C CA2767614 C CA 2767614C
Authority
CA
Canada
Prior art keywords
dose
administered
hours
administration
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2767614A
Other languages
English (en)
Other versions
CA2767614A1 (fr
Inventor
Ronald Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrevus Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of CA2767614A1 publication Critical patent/CA2767614A1/fr
Application granted granted Critical
Publication of CA2767614C publication Critical patent/CA2767614C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

La présente invention concerne de nouveaux schémas posologiques pour le traitement et la prévention d?infections bactériennes à l?aide d?acide fusidique. Il a été découvert que l?utilisation d?une dose de charge élevée d?acide fusidique, suivie de doses d?entretien modérées du médicament, prévient le développement de souches de bactéries résistant au médicament, augmente le spectre efficace du médicament, et évite les nausées et vomissements associés à un traitement prolongé avec des quantités élevées du médicament.
CA2767614A 2009-07-13 2009-07-13 Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes Active CA2767614C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/050353 WO2011008193A1 (fr) 2009-07-13 2009-07-13 Schémas posologiques de l’acide fusidique pour le traitement d’infections bactériennes

Publications (2)

Publication Number Publication Date
CA2767614A1 CA2767614A1 (fr) 2011-01-20
CA2767614C true CA2767614C (fr) 2019-01-15

Family

ID=43449613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2767614A Active CA2767614C (fr) 2009-07-13 2009-07-13 Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes

Country Status (2)

Country Link
CA (1) CA2767614C (fr)
WO (1) WO2011008193A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (fr) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Nouveaux agents antibactériens
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2362727B1 (fr) 2008-10-24 2018-04-11 Cempra Pharmaceuticals, Inc. Procédés de traitement de maladies résistantes en utilisant des macrolides contenant du triazole
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
SI2571506T1 (sl) 2010-05-20 2017-12-29 Cempra Pharmaceuticals, Inc. Postopki za pripravo makrolidov in ketolidov ter njihovih intermediatov
WO2012034058A1 (fr) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Fluorocétolides formant des liaisons hydrogène pour traiter les maladies
JP6208742B2 (ja) 2012-03-27 2017-10-04 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質を投与するための非経口製剤
WO2014152326A1 (fr) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Procédés pour traiter des maladies respiratoires et formulations pour la mise en œuvre de ceux-ci
US9751908B2 (en) 2013-03-15 2017-09-05 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
US9345717B2 (en) 2013-09-25 2016-05-24 Zavante Therapeutics, Inc. Method for improving drug treatments in mammals

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4184607B2 (ja) * 1998-09-25 2008-11-19 キュービスト ファーマシューティカルズ， インコーポレイテッド 抗生剤の投与方法
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition

Also Published As

Publication number Publication date
WO2011008193A1 (fr) 2011-01-20
CA2767614A1 (fr) 2011-01-20

Similar Documents

Publication Publication Date Title
CA2767614C (fr) Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes
US8450300B2 (en) Fusidic acid dosing regimens for treatment of bacterial infections
US8420592B2 (en) Methods of treatment using single doses of oritavancin
US20130164351A1 (en) Methods of treating bacterial infections through pulmonary delivery of fusidic acid
JPH02502459A (ja) リポソーム含有ニスタチン
CA2760159C (fr) Procedes de traitement d'infections bacteriennes a l'aide d'oritavancine
WO2016116892A1 (fr) Compositions antibactériennes
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
JP2997202B2 (ja) 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ
JPH07118169A (ja) 抗菌製剤及び抗真菌製剤
Allendoerfer et al. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis
US8916543B1 (en) Inhibitors of alpha-toxin
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
CN110801455B (zh) 用于治疗mrsa的药物组合物及其应用
WO2015031579A2 (fr) Méthodes de traitement d'infections bactériennes au moyen d'oritavancine et de polymyxines
US20160243144A1 (en) Fixed dose combination formulations of rifaximin and lactulose
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
US20170119793A1 (en) Compositions and methods for treating bone and joint infections
JP2020508299A (ja) 非ヒト動物におけるグラム陽性菌及びグラム陰性菌に起因する疾患に対するリソバクチンとアミノグリコシド類の組み合わせ
Jacqueline et al. Antibiotics Against Endocarditis–Past, Present and Future (Experimental Data)
US20070072814A1 (en) Method and means of modulating lipid metabolism

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140623